TARA
Protara Therapeutics, Inc.
Key Financials
Net Income
$-57439000
↓ 28.8%
Operating Income
$-64549000
↓ 31.3%
Revenue
$2.9M
0.0%
EPS (Diluted)
$-1.34
↑ 38.2%
Total Assets
$209.5M
↑ 15.4%
Total Liabilities
$13.1M
↓ 8.8%
Shareholders' Equity
$196.4M
↑ 17.5%
Cash & Equivalents
$49.7M
↓ 69.5%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| SCHEDULE 13G/A | 8/13/2026 | View on SEC |
| S-8 | 8/11/2026 | View on SEC |
| 10-Q | 8/11/2026 | View on SEC |
| 8-K | 8/11/2026 | View on SEC |
| SCHEDULE 13G/A | 7/7/2026 | View on SEC |
| 4 | 7/1/2026 | View on SEC |
| 8-K | 6/29/2026 | View on SEC |
| 144 | 6/29/2026 | View on SEC |
| 4 | 6/16/2026 | View on SEC |
| 4 | 6/16/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | TARA |
| Company Name | Protara Therapeutics, Inc. |
| CIK | 1359931 |
| Sector | Biological Products, (No Diagnostic Substances) |
| Industry | Non-accelerated filer Smaller reporting company |
| Exchange | Nasdaq |
| SIC Code | 2836 |
| SIC Description | Biological Products, (No Diagnostic Substances) |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| Phone | 646-844-0337 |